Optimizing IGF-I for skeletal muscle therapeutics

Growth Horm IGF Res. 2014 Oct;24(5):157-63. doi: 10.1016/j.ghir.2014.06.003. Epub 2014 Jun 19.

Abstract

It is virtually undisputed that IGF-I promotes cell growth and survival. However, the presence of several IGF-I isoforms, vast numbers of intracellular signaling components, and multiple receptors results in a complex and highly regulated system by which IGF-I actions are mediated. IGF-I has long been recognized as one of the critical factors for coordinating muscle growth, enhancing muscle repair, and increasing muscle mass and strength. How to optimize this panoply of pathways to drive anabolic processes in muscle as opposed to aberrant growth in other tissues is an area that deserves focus. This review will address how advances in the bioavailability, potency, and tissue response of IGF-I can provide new potential directions for skeletal muscle therapeutics.

Keywords: Anabolism; Hypertrophy; Isoforms; Post-translational processing; Satellite cells.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Insulin-Like Growth Factor I / chemistry
  • Insulin-Like Growth Factor I / therapeutic use*
  • Muscle, Skeletal* / drug effects
  • Muscle, Skeletal* / pathology
  • Muscle, Skeletal* / physiology
  • Muscular Diseases / drug therapy*
  • Protein Isoforms
  • Receptor, IGF Type 1 / agonists
  • Regeneration / drug effects
  • Satellite Cells, Skeletal Muscle / drug effects
  • Satellite Cells, Skeletal Muscle / physiology

Substances

  • Protein Isoforms
  • Insulin-Like Growth Factor I
  • Receptor, IGF Type 1